Emerging World Pharma Inc. Management Approves Investment Allocation Into European Global Pharma

   Emerging World Pharma Inc. (PINKSHEETS: EWPI) president, Brandon Keks, confirmed today that the company has approved an ongoing investment allocation into European Global Pharma. The first allotment of funding has been set aside as the company completes its due diligence. "We do not anticipate any delays or anomalies regarding this initial investment and the monies should be released by May 1, 2010," noted Mr. Keks.

The investment will be used to fund generic drug manufacturing facilities in Estonia and eventually expand into Eastern European countries.

Mr. Keks added, "We believe the investment into European Global Pharma via Estonia will provide a corridor for continued growth and development of generic pharmaceutical manufacturing into Eastern Europe and surrounding Baltic regions."

The company's investment into African Global Pharma Sunyani, Ghana's generic pharmaceutical facility, is on schedule to be operational by the end of May 2010.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations. The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: [e-mail]